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Immune evasion and deregulation of energy metabolism play a pivotal role in cancer 
progression. Besides the coincidence in their historical documentation and concurrent 
recognition as hallmarks of cancer, both immune evasion and metabolic deregulation 
may be functionally linked as well. For example, the metabolic phenotype, particularly 
tumor glycolysis (aerobic glycolysis), impacts the tumor microenvironment (TME), which 
in turn acts as a major barrier for successful targeting of cancer by antitumor immune 
cells and other therapeutics. Similarly, in the light of recent research, it has been known 
that some of the immune sensitive antigens that are downregulated in cancer may also 
be restored or induced by cellular/metabolic stress. For instance, cancer cells down-
regulate the cell surface ligands such as MHC class I chain-related (MIC) protein-(A/B) 
that are normally upregulated in disease/pathological conditions. Noteworthy, the MHC 
class I chain-related protein A and B (MIC-A/B) are recognized by natural killer (NK) cells 
for immune elimination. Interestingly, MIC-A/B is stress inducible as demonstrated by 
oxidative stress and other cellular-stress factors. Consequently, stimulation of metabolic 
stress has also been shown to sensitize cancer cells to NK cell-mediated cytotoxicity. 
Taken together, data from recent reports imply that dysregulation of tumor glycolysis 
could facilitate induction of immune sensitive surface ligands leading to increased effi-
cacy of antitumor immunotherapeutics. Nonetheless, dysregulated tumor glycolysis may 
also impact the TME and alter it from acidic, low pH into a therapeutically desirable TME 
that can enhance the effective infiltration of antitumor immune cells. In this mini-review, 
targeting tumor glycolysis has been discussed to evaluate its potential implications to 
enhance and/or facilitate anticancer immunity.
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inTRODUCTiOn
Among different cancer treatment modalities immunotherapy enjoys the advantage of antigen-
dependent specific targeting of cancer cells. Although the therapeutic potential of host immune 
system in affecting cancer progression has long been known (1), only in the recent decades research 
on the development of effective immunotherapy has gained momentum. Approval of immuno-
therapeutics by the Food and Drug Administration (USA) further signified immunotherapy as one 
of the potent and viable approaches for cancer treatment (2). During the recent expansion of the 
FiGURe 1 | A schematic showing major immune-evasive mechanisms 
that enable cancer cells to escape immune surveillance and 
antitumor immunity.
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list of hallmarks of cancer, Hanahan and Weinberg (3) included 
“immune-evasion” and the “deregulation of energy metabolism” 
(i.e., metabolic reprogramming also referred as “altered energy 
metabolism”) as additional molecular signatures of cancer. Both 
the “deregulated energy metabolism” and the immune evasion 
occupy similar chronological history in terms of their initial 
documentation (more than several decades ago) (4, 5), followed 
by decades of paucity and the recent recognition as cancer hall-
marks (3). Emerging reports suggest that besides the historical 
coincidence, these two phenotypes may be functionally linked 
as well (6). This mini-review aims at understanding the role of 
tumor glycolysis in the context of immune evasion and to discuss 
potential immunotherapeutic implications of taming tumor 
glycolysis.
CAnCeR iMMUne evASiOn
Cancer cell’s propensity to escape immune surveillance is known 
as cancer immune evasion (3). Substantial body of evidence 
unequivocally demonstrate that cancer cells employ several 
lines of biochemical and functional alterations to evade immune 
detection (7). Such immune-evasive mechanisms include 
cancer-derived immune modulators, upregulation of immune 
checkpoint molecules, and downregulation of tumor-specific 
antigens (Figure  1). Cancer-associated immune modulation 
is achieved via certain secretory products that include but are 
not limited to (i) cytokines (e.g., interleukins), (ii) chemokines 
(e.g., SDF-1) that promote the activation of tumor-associated 
macrophages, and (iii) establishment of an acidic tumor 
microenvironment (TME) that renders majority of antitumor 
immune cells less efficient or non-functional (8). Next, immune 
checkpoint ligands prevent or suppress the antitumor activity 
of immune cells by inhibitory interaction with corresponding 
receptors on immune cells. For example, the expression of CD80 
ligand on cancer cell enables it to inhibit the immune reaction 
of cytotoxic T lymphocytes (CTL) by binding with the specific 
receptor CTLA4. Similarly, the programmed death-ligand 
(PD-L 1,2) interferes with the antitumor function of CTLs by 
binding with PD-1 receptor. Finally, the downregulation of can-
cer-specific antigens such as major histocompatibility complex 
(MHC) molecules has been implicated as one of the prominent 
mechanisms to escape immune detection by T  lymphocytes. 
Recent data indicate such downregulation also includes the 
antigens specific for natural killer (NK) cells. Experimental 
evidences on the ligands, MHC class I chain-related protein A 
or B (MIC-A/B) demonstrates that cancer cells downregulate 
these NKG2D ligands to prevent immune recognition by cor-
responding receptors on NK cells (9). Thus, antigens or ligands 
specific for T cells as well as NK cells are downregulated as parts 
of immune-escape mechanisms.
Among the innate (e.g., NK  cells) and adaptive immune 
systems (e.g., T-cells), the latter has been under extensive 
preclinical and clinical investigation. Therefore, significant 
progress has been made in understanding the mechanistic 
details of T-cell-mediated antitumor immunity, leading to 
the development of potential therapies by harnessing T-cell’s 
ability to target cancer (10). For instance, the development of 
monoclonal antibodies (mAbs) against specific cancer antigens 
or tumor antigens has been very effective in specific targeting to 
enhance T-cell-mediated immunotherapy (11). However, such 
mAbs were frequently challenged with undesirable effects like 
the immunogenicity in patients and reduced efficiency in the 
recruitment of effectors cells (12). Hence, additional approaches 
were undertaken to overcome at least some of the impediments 
faced by such mAbs. Consequently, humanized chimeric antigen 
receptor (CAR)-T cells were developed which markedly reduced 
the undesirable immune reactions. However, the clinical out-
comes were still less successful necessitating further research 
(12). Nevertheless, T-cell-dependent or -related potential 
therapeutics are advancing at an exponential rate toward the 
development of a viable strategy to achieve successful cancer 
treatment. Meanwhile, studies on the innate immune system 
such as NK cells have also been progressing remarkably to exploit 
potential opportunities for cancer therapy (13–15). Especially 
the adoptive cells transfer therapy has shown promising results 
and encouragement. Yet, irrespective of the type of immune 
therapeutics, the clinical benefits of immunotherapy have been 
realized primarily in hematological cancers (16, 17) and less 
efficient against solid malignancies.
TUMOR GLYCOLYSiS
Several elegant reviews have discussed the biology and signifi-
cance of tumor glycolysis (18, 19). Hence, considering the focus 
of this review, the tumor glycolysis will be discussed in the context 
of its role and relevance in immune evasion and immunotherapy, 
respectively. Clinical diagnosis of cancer using positron emission 
tomography relies on the accelerated rate of glucose metabolism, 
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one of the metabolic signatures of cancer cells (20). This increased 
glucose utilization is accomplished by a metabolic switch to 
glycolysis, i.e., the process of conversion of glucose into pyru-
vate followed by lactate production in the absence of oxidative 
phosphorylation (OxPhos). The pioneering work of the German 
scientist, Warburg (5, 21) documented for the first time that can-
cer cells exhibit glycolysis even in the presence of oxygen, hence 
popularly known as “aerobic glycolysis” or “Warburg effect.” 
Aerobic  glycolysis or the tumor glycolysis produces fewer energy 
molecules (e.g., ATP) compared to the mitochondrial, OxPhos. 
Several elegant reviews (18, 22) have provided insights on the 
biological effects and advantages of such a “metabolic switch.” In 
fact, the metabolic switch or the “altered energy metabolism” is 
so frequent and common in majority, if not, all types of cancers, 
it has been included as one of the hallmarks of cancer (3). In this 
context, it is noteworthy that recent research demonstrates that 
aggressive phenotype of cancer is also associated with increased 
OxPhos, which relies on mitochondrial respiration (23, 24). 
However, considering the aim of this mini-review and the space 
limitation, the discussion on tumor metabolism will be limited 
to tumor glycolysis.
Clinically, tumor glycolysis has been found to be associated 
with some of the therapeutic challenges that impede success-
ful cancer treatment. For example, tumor glycolysis has been 
implicated in therapeutic resistance (25) in chemotherapy (26), 
radiation therapy (27), etc. In this context, the TME has been 
implicated as one of the major barriers for successful targeting of 
cancer (28, 29). The composition of TME is primarily influenced 
by secretory/excretory products of cancer cells in addition to 
the tumor-associated fibroblasts. Lactate produced by glucose 
metabolism, particularly the glycolysis, is secreted/exported 
and remains in the TME. Hence, tumor glycolysis is one of the 
chief metabolic principles that orchestrate the constituents of 
TME. The extracellular accumulation of lactate contributes to 
the chemical gradient and pH of the TME (30). Experimental 
evidences demonstrate that the low pH or the acidity of TME 
either impedes the penetrability of therapeutics or renders 
them inactive and non-functional (30). Accordingly, effective 
elimination of cancer necessitates the integration of a strategy to 
overcome the TME barrier.
Tumor glycolysis contributes to the acidic microenviron-
ment through the release of lactate and other low-pH ions into 
the extracellular milieu that in turn prevents or quenches the 
infiltration or efficacy of therapeutics. Thus, it is evident that 
tumor glycolysis invariably facilitates a protective barrier and 
maintains the efficient management cellular bioenergetics and 
redox balance in cancer. Thus, disruption of tumor glycolysis is 
imperative to destabilize cancer cells’ redox balance rendering 
them susceptible to therapeutic intervention. One of the well-
investigated targets for the inhibition of tumor glycolysis is the 
enzyme, lactate dehydrogenase (LDH), the enzyme that catalyzes 
the conversion of pyruvate into lactate (31). Besides the inhibi-
tion of LDH, tumor glycolysis may also be disrupted by targeting 
any intermediate steps of glucose metabolism. For instance, 
inhibition of the enzyme hexokinase (32) or any other enzymes 
(33, 34) that catalyze subsequent reactions of glucose metabolism 
has been known to promote anticancer effects. Noteworthy, there 
is a distinctive advantage in targeting glycolytic steps preceding 
the step of lactate production. In other words, deregulation of 
tumor glycolysis by targeting glycolytic enzymes other than LDH 
may have additional desirable outcome. This is primarily due to 
the characteristic, “feed-back” inhibitory mechanism of glucose 
metabolism. Precisely, the accumulation metabolites of interme-
diate steps of glycolysis due to the inhibition of a particular enzyme 
eventually blocks or alleviates the rate of glucose catabolism in a 
negative feedback fashion. Thus, disruption of tumor glycolysis 
plausibly reduces the rate of glucose oxidation and utilization. 
Consequently, the energy demands of cancer cells will neces-
sitate the utilization of alternative energy producing pathways, 
which is plausible due to the metabolic plasticity of cancer cells. 
One of the alternative pathways frequently witnessed in cancer 
cells to meet their energy demand is the glutamine metabolism, 
which relies on mitochondrial respiration. Thus, dysregulation 
of tumor glycolysis will necessitate cancer cells to depend on 
mitochondrial metabolism rendering them susceptible to any 
anti-mitochondrial approach using mitotropic agents (35, 36). 
Moreover, such unidirectional metabolic switch to mitochondrial 
metabolism also blocks the capacity of cancer cells to reprogram 
to glycolysis as the glucose consumption remains impaired due to 
the inhibition of glycolysis.
DYSReGULATiOn OF TUMOR 
GLYCOLYSiS AnD iMMUnOSenSiTiviTY
As discussed above, in the absence of OxPhos, lactate is the 
metabolic end product of tumor glycolysis. The lactate thus 
produced is then exported to the external milieu via specific 
transporters called monocarboxylate transporters (MCTs). 
Lactate is a major source of the H+ ions that contributes to 
the acidification of TME, although other sources of H+ ions 
are prevalent (37). Disruption or dysregulation of glycolysis by 
the inhibition of LDH has been shown to rewire the metabo-
lism toward mitochondrial-dependent OxPhos (38). Though 
such a metabolic plasticity allows cancer cells to survive, 
the intrinsic characteristics of OxPhos have been known as 
undesirable for the perpetuation of tumor growth. One of the 
metabolic outcomes of OxPhos is the generation of free radicals 
collectively known as reactive oxygen species (ROS). ROS is 
required for the stabilization of one of the critical factors, the 
hypoxia inducible factor (HIF)-1 (39). Conversely, excessive 
accumulation of ROS is deleterious to subcellular structures 
and organelles (40). In fact, some of antineoplastic alkylating 
agents exert anticancer effects by the induction of ROS to 
cytotoxic levels (41). Next, as chronic accumulation of ROS is 
deleterious to subcellular organelles/membrane structures, it 
necessitates their neutralization or quenching by antioxidants 
(e.g., glutathione). In cancer cells, the level of antioxidants has 
been mitigated as the metabolic phenotype is primarily uti-
lized for the synthesis of macromolecules that are critical for 
proliferation and growth. Noteworthy, antioxidants have also 
been implicated as potential anticancer agents as they eliminate 
ROS, which is required for the stabilization of HIF-1 (42). 
Thus, the maintenance of a redox balance with minimal ROS 
production to sustain HIF-1 regulation and downregulation 
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of antioxidants is one of the critical requirements of cancer 
cells. Accordingly, the metabolic switch to glycolysis has been 
ascribed as one of the adaptive mechanisms to reduce the level 
of ROS generated via OxPhos (36).
Next, in solid tumors, the presence of TME has been recog-
nized as one of the major barriers that hinders successful tumor 
elimination by antitumor immune cells. TME is a complex 
medium, which influences and gets influenced by, the metabolic 
phenotype of cancer (43). The biochemical composition and the 
pH of the TME are primarily governed by the secretory/excre-
tory products of cancer cells as well as the adjacent stromal cells 
or cancer-associated fibroblasts (CAFs). Emerging data indicate 
that CAFs play a pivotal role in the maintenance of tumor growth 
(44). CAFs have been known to utilize one of the metabolic 
products of cancer, the lactic acid or lactate. Removal of lactate 
by CAFs regulates/reduces chronic extracellular acidification. In 
addition, the utilization of lactate by CAFs via mitochondrial 
OxPhos to meet their energy demands reduces their demand for 
glucose, leading to increased glucose availability for cancer cells. 
Thus, CAFs indirectly facilitate glucose availability to fuel tumor 
metabolism. If tumor glycolysis is disrupted and lactate produc-
tion is alleviated, the CAFs will rely on glucose metabolism lead-
ing to a competition with cancer cells for glucose uptake. Thus, 
disruption of tumor glycolysis will necessitate cancer cells to 
utilize mitochondrial-dependent OxPhos to meet their energy 
requirements. This in turn would deregulate the redox balance 
due to overly production of ROS. In addition, such an increase 
in intracellular ROS level along with a competition by CAFs 
for glucose consumption likely to enforce a metabolic pressure. 
Thus, dysregulation of tumor glycolysis could render cancer cells 
metabolically weak and sensitive to therapeutic interference.
From the immunotherapy perspective, the abrogation or 
reduction of lactate production that in turn reduces the acidifica-
tion of TME is a desirable consequence for effective infiltration 
of therapeutics including immune cells. Noteworthy, low pH 
and increased acidification of TME are principal reasons for 
the lack of efficacy or loss of function of several therapeutics 
including chemotherapeutics and immunotherapeutics (45). 
Comprehensibly, reduced acidification would facilitate enhanced 
penetrability of antitumor immune cells such as T-cells or 
NK cells or novel therapeutics like CAR-T cells (Figure 2A). In 
fact, sporadic reports have indicated that disruption of tumor 
glycolysis to limit the accumulation of lactate in TME could 
promote antitumor immune response (6, 46). Thus, dysregulation 
of glycolysis in cancer cells could facilitate effective targeting of 
cancer by antitumor immune cells.
Next, the NK  cells represent the first line of defense, and 
preclinical reports indicate that NK cell-mediated cytotoxicity 
affects cancer cells (13, 47). However, recognition of cancer 
cells by NK  cells depends upon two critical factors; (a) the 
recognition of specific antigens known as NK group 2D ligands 
(NKG2DLs) on the cancer cell and (b) the infiltration through 
TME. As discussed above, the latter may be overcome by 
dysregulation of tumor glycolysis, which will alter the acidic 
TME into less-acidic medium enabling effective infiltration 
of NK  cells. However, the NK  cell recognition of cancer by 
specific NKG2D ligands such as ULBP, MIC-A/B relies on 
their level of expression on target cells. Paradoxically, cancer 
cells downregulate the expression of NKG2DLs. Besides the 
reduction in expression, cancer cells have also been known to 
cleave the extracellular domain of the ligands like MIC-A/B, 
and such cleavage results in the release of soluble ligands. These 
soluble cleaved-products bind with specific NK cell receptors 
resulting in the neutralization of NK cell activity (Figure 2B). 
Intriguingly, recent reports show that MIC-A/B is stress induc-
ible and is upregulated during cellular stress, such as oxidative 
stress (48) or thermal stress (49). In fact, recent experimental 
evidence shows that metabolic perturbation induces the expres-
sion of MIC-A/B (50). Thus, interference with tumor glycolysis 
and subsequent metabolic stress is a potential inducer of MIC-
A/B expression, which could render cancer cells sensitive to 
NK cell-mediated cytotoxicity (Figure 2B).
COnCLUSiOn
Mounting evidence establish that tumor-specific alteration in 
energy metabolism could be the Achilles’ heel of cancer (51). 
It is also clear that glycolytic phenotype influences the TME. 
Particularly, the impediments like acidic and low pH that hinder 
efficacy of majority of therapeutics including infiltrating anti-
tumor immune cells. Thus, dysregulation of tumor glycolysis 
has the potential to sensitize cancer cells to NK cell-mediated 
immunotherapy by the upregulation of stress-inducible 
NKG2DLs (MIC-A/B) and affect the acidity of TME rendering 
increased penetrability or infiltration of antitumor immune 
cells (Figure 2C). However, to achieve cancer-specific glycolytic 
dysregulation and to enhance the effectiveness of anticancer 
immunotherapeutics, it is imperative to overcome some major 
challenges. Selective inhibition of glycolysis in cancer cells but 
not of healthy cells is the primary requirement. In this context, 
recent preclinical evidences have indicated the feasibility of 
selective targeting of tumor glycolysis by small molecules that 
rely on cancer-specific upregulation transporters like MCT-1 
(52, 53). Nonetheless, detailed clinical investigations are man-
datory to ascertain the translational potential of such molecules 
and strategies. Next, emerging reports demonstrate that inhibi-
tion of glycolysis or glucose deprivation facilitates metabolic 
switch to OxPhos in some cancers and lead to aggressive phe-
notype (e.g., metastasis) (54). In such glycolytically impaired 
but OxPhos dependent cancer cells, therapeutic targeting of 
mitochondrial respiration using potential anti-mitochondrial 
or mitotropic agents could be a viable anticancer approach 
(35, 55). However, the impact of such metabolically altered 
phenotype in its sensitivity to anticancer immune therapeutics 
remains to be investigated. Nonetheless, the antiglycolytic 
approach-related changes in TME may still yield favorable 
outcomes with anticancer immune therapeutics.
Next, the dysregulation of tumor glycolysis needs to be 
achieved by a strategy or therapeutic that is less toxic to 
circumvent the problem of inadvertent or undesirable effects 
on NK  cells’ efficacy. Similarly, one of the common causes of 
diminished antitumor immunity is the undesirable toxicity that 
emanates from prior treatments. This is prevalent in cases of 
prior chemotherapy as the effective dose of chemotherapy relies 
FiGURe 2 | Potential anticancer immunotherapeutic opportunities of dysregulation of tumor glycolysis. (A) A schematic showing that dysregulation of 
tumor glycolysis alters tumor microenvironment that in turn could facilitate effective infiltration of antitumor immune cells. (B) Diagrammatic representation of 
dysregulation of tumor glycolysis to upregulate the stress-inducible surface ligands for further sensitization to natural killer (NK) cell-mediated cytotoxicity.  
(C) A schematic showing potential outcomes of induction of metabolic stress by dysregulation of tumor glycolysis.
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on maximum tolerated dose, whereas such doses are invari-
ably toxic and affect the maturation or functional activation 
of immune cells (56). Thus, any agent employed to dysregulate 
tumor glycolysis should be sufficient to disrupt the metabolic 
process but not toxic. Indeed, it is preferred that such glycolytic 
inhibition does not kill cancer cells, as the goal is to sensitize 
cancer cells to immunotherapy, which in turn will enable us 
to expand the repertoire of antitumor immunity. Such low-
dose chemotherapeutics have also been shown to enhance the 
effectiveness of anticancer immunotherapy (57). Thus, future 
studies on the selective dysregulation of tumor glycolysis to 
alter TME and the related therapeutic resistance could advance 
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